Scilex Holding Company (SCLX) is a Palo Alto–based commercial-stage pharmaceutical company that sells non-opioid pain therapies, including the lidocaine patch ZTlido, the migraine solution ELYXYB, and the gout treatment GLOPERBA, while developing injectable and topical candidates for sciatica and chronic pain. On Tuesday, the stock traded at $0.82, a decline of 34.40% from the previous session's close of $1.25. The direction was unambiguously lower. Monday's close had already marked a 12.59% drop, meaning the shares have now fallen in twelve of the past fifteen sessions. No verified news catalyst was identified for the session's losses.
No verified news or fundamental catalyst found in company releases, regulatory filings, or wire reports explains a move of this size on Tuesday. Pre-market indications near $1.26 gave way to immediate selling at the open, and the stock deteriorated steadily through the morning — price action more consistent with a thin order book absorbing a modest wave of sell orders than with a single discrete event. With about 7 million shares outstanding and average daily turnover near 42,000 shares, SCLX is a micro-cap where a few thousand shares can shift the quote by several cents. That structural fragility, rather than fresh information, is the most plausible mechanical driver of the session.
The broader decline is grounded in verified fundamentals. Third-quarter revenue came in at roughly $7.6 million, down about 23% year over year, while the quarterly net loss widened sharply to roughly $114 million from $42 million a year earlier. Full-year 2025 revenue had already fallen more than 46% to $30.25 million. The balance sheet is the sharper problem: cash of about $581,000 against total debt near $106 million, a current ratio of 0.07, and negative book value. A $500 million mixed-securities shelf registration creates a persistent dilution overhang, and a proposed $100 million strategic investment at $15.00 per share announced in July remains conditional on diligence and approvals. Each of these items predates Tuesday's move, but together they explain why sellers meet every rebound.
The selling was company-specific. No comparably sized decline was under way across healthcare or small-cap pharmaceuticals, and the move diverged from a broader market that showed no similar stress. Volume was light in absolute terms — only a few hundred shares traded in the first minutes after the open — which magnifies percentage moves. Technically, the picture is severe: the shares sit roughly 75% below their 50-day moving average near $3.30 and about 87% below the 200-day average around $6.40, down roughly 93% over the trailing year. The relative strength index has sunk into the low teens, deep in oversold territory, yet no buying interest has emerged. The sub-$1 print is a new 52-week low and the first close below the dollar threshold.
The scale runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news paired with an extreme, rare price move. SCLX earns 49 out of 100. Verified news strength was minimal: nothing published on Tuesday explained the decline, so the fundamental component reflects only pre-existing distress at a company whose market value is now roughly $7 million. The price component is far stronger. The stock's typical daily move over the past 60 sessions is about 3.5%, and Tuesday's 34.40% decline is nearly ten times that, the largest single-session drop in the sample and well beyond the 12%–15% extremes seen earlier in the autumn. Minimal news plus a statistically extreme move produces a mid-range score.
The next scheduled financial update is estimated for late November, and investors will focus on cash burn, liquidity, and whether management signals a need for external financing. Analysts have largely stepped back from coverage, and consensus price targets are unavailable. Commercially, prescription trends for ZTlido and ELYXYB will matter more than pipeline milestones while resources remain constrained. Key uncertainties include the status of the pending strategic investment, progress on the amended letter of intent covering licensing and intellectual property assets, and any communication regarding listing standards now that the share price is below $1. Further equity issuance remains a live risk given the shelf registration.
Tickeron's Trending AI Robots page highlights a curated selection drawn from hundreds of AI trading bots that cover thousands of tickers. Rather than listing every strategy, it surfaces only the bots posting the strongest performance under current market conditions. The bots differ widely by strategy logic, holding timeframe, performance metrics, and the symbols they trade, so results can vary substantially between models. For traders looking to pair volatility like this with systematic execution, the page is a practical starting point — review the current leaders and compare their parameters before deploying capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SCLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where SCLX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SCLX just turned positive on October 29, 2026. Looking at past instances where SCLX's MACD turned positive, the stock continued to rise in 31 of 42 cases over the following month. The odds of a continued upward trend are 74%.
The 50-day moving average for SCLX moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SCLX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.039) is normal, around the industry mean (-1.421). P/E Ratio (-0.034) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.435) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SCLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor